Melvin Sharoky, a director at Insmed Inc., sold 5,000 common shares of the company indirectly through his entity Padonia LLC on August 17, 2026, according to regulatory filings. The shares were sold at prices ranging from $127.51 to $127.61 per share, totaling approximately $637,650.
The transaction occurred near recent highs, with Insmed’s stock trading at $123.86 shortly after the sale. Sharoky remains a significant shareholder, holding 246,081 shares directly, along with additional holdings through custodial arrangements for family members totaling 21,010 shares. These include 6,847 shares held by his spouse and 17,163 shares managed as custodian for Adler J. Wink, Nolan M. Wink, Sophie C. Wink, and Tulia L. Sharoky under UTMA/FL accounts.
Insmed reported a trailing twelve-month revenue of $1.14 billion, an 186% increase, with a gross profit margin of 83%. Second-quarter product revenue reached $309.2 million for BRINSUPRI and $116.3 million for ARIKAYCE, the latter marking an 8% year-over-year rise. The company raised its 2026 revenue guidance for BRINSUPRI to a range of $1.25 billion to $1.4 billion, while combined peak sales estimates for the company’s top three assets were increased to over $14 billion.
Wall Street analysts have maintained bullish outlooks, with price targets ranging from $169 to $243. Mizuho raised its target to $195 with an
